Amcasertib

Drug Profile

Amcasertib

Alternative Names: BB503; BBI 503; GB-503

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boston Biomedical
  • Developer Boston Biomedical; Sumitomo Dainippon Pharma
  • Class Antineoplastics; Indoles; Pyrroles; Small molecules; Thiazoles
  • Mechanism of Action Cell death stimulants; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Gastrointestinal stromal tumours; Hepatocellular carcinoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 07 Jul 2017 Boston Biomedical withdraws a phase II trial prior to enrolment due to low feasibility for Urogenital cancer (Late-stage disease, Metastatic disease, Unresectable/ Inoperable, Recurrent, Second-line therapy or greater) in USA and Canada (PO) (NCT02232646)
  • 14 Jun 2017 Efficacy and adverse events data from a phase Ib/II trial in solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO 2017)
  • 05 Jun 2017 Interim efficacy and adverse events data from a phase Ib/II trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top